CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration

Bulletin Express

07/10

CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.

The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.

Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.

The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1123700250"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123700250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123700250?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123700250","market":"hk","top_or_hot":-1,"title":"CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.</p>\n<p>The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.</p>\n<p>Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.</p>\n<p>The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-07-10 22:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.</p>\n<p>The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.</p>\n<p>Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.</p>\n<p>The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石藥集團","start_time":0,"source_url":"","article_id":"1123700250","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123700250","pubTimestamp":1783694548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026. The payment arises from the strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团从阿斯利康获得2500万美元长效肽合作研发里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.\nThe payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.\nManagement stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.\nThe companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}